What is the Role of Adiponectin in Obesity Related Non-alcoholic Fatty Liver Disease?

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2013 Feb 23

PMID 23430039

Citations 75

Authors

Carmine Finelli

Giovanni Tarantino

Affiliations

Soon will be listed here.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is recognized as the most common type of chronic liver disease in Western countries. Insulin resistance is a key factor in the pathogenesis of NAFLD, the latter being considered as the hepatic component of insulin resistance or obesity. Adiponectin is the most abundant adipose-specific adipokine. There is evidence that adiponectin decreases hepatic and systematic insulin resistance, and attenuates liver inflammation and fibrosis. Adiponectin generally predicts steatosis grade and the severity of NAFLD; however, to what extent this is a direct effect or related to the presence of more severe insulin resistance or obesity remains to be addressed. Although there is no proven pharmacotherapy for the treatment of NAFLD, recent therapeutic strategies have focused on the indirect upregulation of adiponectin through the administration of various therapeutic agents and/or lifestyle modifications. In this adiponectin-focused review, the pathogenetic role and the potential therapeutic benefits of adiponectin in NAFLD are analyzed systematically.

Citing Articles

Mapping Obesity Trends in Saudi Arabia: A Four-Year Description Study.

Althumiri N, Bindhim N, Al-Rayes S, Alumran A Healthcare (Basel). 2024; 12(20).

PMID: 39451507 PMC: 11507986. DOI: 10.3390/healthcare12202092.

Adipokines in the Crosstalk between Adipose Tissues and Other Organs: Implications in Cardiometabolic Diseases.

Hemat Jouy S, Mohan S, Scichilone G, Mostafa A, Mahmoud A Biomedicines. 2024; 12(9).

PMID: 39335642 PMC: 11428859. DOI: 10.3390/biomedicines12092129.

Could Adverse Effects of Antibiotics Due to Their Use/Misuse Be Linked to Some Mechanisms Related to Nonalcoholic Fatty Liver Disease?.

Tarantino G, Citro V Int J Mol Sci. 2024; 25(4).

PMID: 38396671 PMC: 10888279. DOI: 10.3390/ijms25041993.

What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?.

Tarantino G, Citro V Lipids Health Dis. 2024; 23(1):41.

PMID: 38331795 PMC: 10851522. DOI: 10.1186/s12944-024-02031-1.

The Role of Epigenetic Control of Mitochondrial (Dys)Function in MASLD Onset and Progression.

Caputo V, Tarantino G, Santini S, Fracassi G, Balsano C Nutrients. 2023; 15(22).

PMID: 38004151 PMC: 10675587. DOI: 10.3390/nu15224757.

References

Rogers C, Ajmo J, You M . Adiponectin and alcoholic fatty liver disease. IUBMB Life. 2008; 60(12):790-7. DOI: 10.1002/iub.124. View

Suzuki S, Wilson-Kubalek E, Wert D, Tsao T, Lee D . The oligomeric structure of high molecular weight adiponectin. FEBS Lett. 2007; 581(5):809-14. PMC: 1865574. DOI: 10.1016/j.febslet.2007.01.046. View

Massip-Salcedo M, Zaouali M, Padrissa-Altes S, Casillas-Ramirez A, Rodes J, Rosello-Catafau J . Activation of peroxisome proliferator-activated receptor-alpha inhibits the injurious effects of adiponectin in rat steatotic liver undergoing ischemia-reperfusion. Hepatology. 2007; 47(2):461-72. DOI: 10.1002/hep.21935. View

Kim I, Kim J, Kang J, Song J . Serum leptin as a predictor of fatty liver in 7-year-old Korean children. Ann Nutr Metab. 2008; 53(2):109-16. DOI: 10.1159/000165360. View

Mirza M . Obesity, Visceral Fat, and NAFLD: Querying the Role of Adipokines in the Progression of Nonalcoholic Fatty Liver Disease. ISRN Gastroenterol. 2011; 2011:592404. PMC: 3168494. DOI: 10.5402/2011/592404. View

Polak J, Kovacova Z, Holst C, Verdich C, Astrup A, Blaak E . Total adiponectin and adiponectin multimeric complexes in relation to weight loss-induced improvements in insulin sensitivity in obese women: the NUGENOB study. Eur J Endocrinol. 2008; 158(4):533-41. DOI: 10.1530/EJE-07-0512. View

Kadowaki T, Yamauchi T, Kubota N . The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS. FEBS Lett. 2007; 582(1):74-80. DOI: 10.1016/j.febslet.2007.11.070. View

Farrell G, Larter C . Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006; 43(2 Suppl 1):S99-S112. DOI: 10.1002/hep.20973. View

Matsuzawa Y . Adiponectin: a key player in obesity related disorders. Curr Pharm Des. 2010; 16(17):1896-901. DOI: 10.2174/138161210791208893. View

10.

Gu W, Li Y . The therapeutic potential of the adiponectin pathway. BioDrugs. 2011; 26(1):1-8. DOI: 10.2165/11594790-000000000-00000. View

11.

Liu Q, Bengmark S, Qu S . The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD). Lipids Health Dis. 2010; 9:42. PMC: 2873482. DOI: 10.1186/1476-511X-9-42. View

12.

Fan J, Saibara T, Chitturi S, Kim B, Sung J, Chutaputti A . What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?. J Gastroenterol Hepatol. 2007; 22(6):794-800. DOI: 10.1111/j.1440-1746.2007.04952.x. View

13.

Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M . Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med. 2007; 13(3):332-9. DOI: 10.1038/nm1557. View

14.

Rothan H, Teh S, Haron K, Mohamed Z . A comparative study on the expression, purification and functional characterization of human adiponectin in Pichia pastoris and Escherichia coli. Int J Mol Sci. 2012; 13(3):3549-3562. PMC: 3317727. DOI: 10.3390/ijms13033549. View

15.

Woo Y, Tso A, Xu A, Law L, Fong C, Lam T . Combined use of serum adiponectin and tumor necrosis factor-alpha receptor 2 levels was comparable to 2-hour post-load glucose in diabetes prediction. PLoS One. 2012; 7(5):e36868. PMC: 3353952. DOI: 10.1371/journal.pone.0036868. View

16.

Tsochatzis E, Papatheodoridis G . Is there any progress in the treatment of non-alcoholic fatty liver disease?. World J Gastrointest Pharmacol Ther. 2011; 2(1):1-5. PMC: 3091161. DOI: 10.4292/wjgpt.v2.i1.1. View

17.

Vrachnis N, Belitsos P, Sifakis S, Dafopoulos K, Siristatidis C, Pappa K . Role of adipokines and other inflammatory mediators in gestational diabetes mellitus and previous gestational diabetes mellitus. Int J Endocrinol. 2012; 2012:549748. PMC: 3328961. DOI: 10.1155/2012/549748. View

18.

Tomita K, Oike Y, Teratani T, Taguchi T, Noguchi M, Suzuki T . Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice. Hepatology. 2008; 48(2):458-73. DOI: 10.1002/hep.22365. View

19.

Takahashi Y, Soejima Y, Fukusato T . Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2012; 18(19):2300-8. PMC: 3353364. DOI: 10.3748/wjg.v18.i19.2300. View

20.

Vuppalanchi R, Marri S, Kolwankar D, Considine R, Chalasani N . Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis? A preliminary human study. J Clin Gastroenterol. 2005; 39(3):237-42. DOI: 10.1097/01.mcg.0000152747.79773.2f. View